免疫療法聯(lián)合或不化療在基因突變非小細胞肺癌中作用

<br/>WhenTKIsFail:<br/>RoleofImmunotherapyAloneandinCombinationwithChemotherapyinOncogenic-DrivenNSCLC<br/>

<br/>PresentedByCoreyLangerat2019ASCOAnnualMeetingDisclosures:Past8yrsPresentedByCoreyLangerat2019ASCOAnnualMeetingSlide3PresentedByCoreyLangerat2019ASCOAnnualMeetingTKIRefractoryNSCLC<br/><br/>Whathappensafterfirstlinetherapyfails?PresentedByCoreyLangerat2019ASCOAnnualMeetingAcquiredResistanceisInevitableinOncogenic-DrivenNSCLCPresentedByCoreyLangerat2019ASCOAnnualMeetingAttimeofdiseaseprogressiononTKIPresentedByCoreyLangerat2019ASCOAnnualMeetingSlowRECISTProgressioninEGFRM+treatedwithgefitinibPresentedByCoreyLangerat2019ASCOAnnualMeetingSlide8PresentedByCoreyLangerat2019ASCOAnnualMeetingTKI-RefractoryNSCLCPresentedByCoreyLangerat2019ASCOAnnualMeetingChemotherapy!DatafromIPASSPresentedByCoreyLangerat2019ASCOAnnualMeetingOngoingEGFRTKI:IMPRESSTrialPresentedByCoreyLangerat2019ASCOAnnualMeetingOS(ITT;33%ofevents)PresentedByCoreyLangerat2019ASCOAnnualMeetingIMPRESS:MatureOSDataPresentedByCoreyLangerat2019ASCOAnnualMeetingIMPRESS:OSBasedonT790StatusPresentedByCoreyLangerat2019ASCOAnnualMeetingNEJ009PresentedByCoreyLangerat2019ASCOAnnualMeetingNEJ009PresentedByCoreyLangerat2019ASCOAnnualMeetingNEJ009PresentedByCoreyLangerat2019ASCOAnnualMeetingCheckpointBlockadePresentedByCoreyLangerat2019ASCOAnnualMeetingOverallSurvival:KN24PresentedByCoreyLangerat2019ASCOAnnualMeetingKEYNOTE-024StudyDesign(NCT02142738)PresentedByCoreyLangerat2019ASCOAnnualMeetingAPhaseIIStudyofPembrolizumabinEGFR-Mutant,PD-L1+,TyrosineKinaseInhibitorNaivePatientsWithAdvancedNSCLC.PresentedByCoreyLangerat2019ASCOAnnualMeetingPembroMonotherapyinPDL1(+),EGFRmt(+),Tx-na?veNSCLCPresentedByCoreyLangerat2019ASCOAnnualMeetingPembroMonotherapyinPDL1(+),EGFRmt(+),Tx-na?veNSCLCPresentedByCoreyLangerat2019ASCOAnnualMeetingWhataboutsingleAgentCPIin2ndLineSettinginEGFRmt(+)<br/>NSCLCorinLANSCLC?PresentedByCoreyLangerat2019ASCOAnnualMeetingTreatmentEffectonOSinPredefinedSubgroupsinCM057PresentedByCoreyLangerat2019ASCOAnnualMeetingSlide26PresentedByCoreyLangerat2019ASCOAnnualMeeting<br/>OAK:OSINSelectedSUBGROUPSPresentedByCoreyLangerat2019ASCOAnnualMeetingSlide28PresentedByCoreyLangerat2019ASCOAnnualMeetingPACIFIC:PFSSubgroupAnalysisbyBICR(ITT)PresentedByCoreyLangerat2019ASCOAnnualMeetingIMMUNOTARGETPresentedByCoreyLangerat2019ASCOAnnualMeetingIsthereaRoleforCPIinCombinationwithChemoin<br/>AdvancedNCLC<br/>PDL1Agnostic<br/>TKI-Refractory?PresentedByCoreyLangerat2019ASCOAnnualMeetingIMpower150studydesignPresentedByCoreyLangerat2019ASCOAnnualMeetingSlide33PresentedByCoreyLangerat2019ASCOAnnualMeetingUpdatedPFSAnalysisintheITT-WTArmBvsArmCPresentedByCoreyLangerat2019ASCOAnnualMeetingIMpower150:PFSinEGFR-mtpatients-UpdatedatTTLC2019PresentedByCoreyLangerat2019ASCOAnnualMeetingPFSforArmBvsCinEGFR/ALK+PatientsPresentedByCoreyLangerat2019ASCOAnnualMeetingPFSforArmBvsCinPtsWithActionableEGFRMutations(Exon19DeletionorL858RMutation)PresentedByCoreyLangerat2019ASCOAnnualMeetingOSinITT-WT(ArmBvsArmC)PresentedByCoreyLangerat2019ASCOAnnualMeetingSlide39PresentedByCoreyLangerat2019ASCOAnnualMeetingImplicationsofIMP150inALK/EGFR(+)TKI-RefractoryPtsPresentedByCoreyLangerat2019ASCOAnnualMeetingTKI-CPICombinationsinOncogene-AddictedNSCLCPresentedByCoreyLangerat2019ASCOAnnualMeetingTKI-CPICombinationsinOncogene-AddictedNSCLCPresentedByCoreyLangerat2019ASCOAnnualMeetingPD1/PDL1inhibitorsandtargetedtherapyPresentedByCoreyLangerat2019ASCOAnnualMeetingPD1/PDL1inhibitorsandtargetedtherapyPresentedByCoreyLangerat2019ASCOAnnualMeetingPD1/PDL1inhibitorsandtargetedtherapyPresentedByCoreyLangerat2019ASCOAnnualMeetingTatton—Osimertinib/durvalumabPresentedByCoreyLangerat2019ASCOAnnualMeetingOsimertinib/IOleadstoincreasedILDPresentedByCoreyLangerat2019ASCOAnnualMeetingSlide48PresentedByCoreyLangerat2019ASCOAnnualMeetingIntroductionandStudyDesignPresentedByCoreyLangerat2019ASCOAnnualMeetingPatientCharacteristicsandSafety<br/>CombinationAtezolizumabandErlotinibPresentedByCoreyLangerat2019ASCOAnnualMeetingClinicalActivity(Stage2)<br/>PresentedByCoreyLangerat2019ASCOAnnualMeetingSlide52PresentedByCoreyLangerat2019ASCOAnnualMeetingALKTKI+PDL1inhibitionPresentedByCoreyLangerat2019ASCOAnnualMeetingSlide54PresentedByCoreyLangerat2019ASCOAnnualMeetingSevereimmune-relatedadverseeventsarecommon<br/>withsequentialPD-(L)1blockadeandosimertinibPresentedByCoreyLangerat2019ASCOAnnualMeetingOsiPD(L)1MAbvsPD(L)1MAbOsiPresentedByCoreyLangerat2019ASCOAnnualMeetingOsiPD(L)1MAbvsPD(L)1MAbOsiPresentedByCoreyLangerat2019ASCOAnnualMeetingActivatingMutationsand